(Reuters) - The Phase III trials were designed to compare the efficacy
and safety of iclaprim in the treatment of skin infections with
that of market leader linezolid, marketed by Pfizer as Zyvox.
"The pre-specified primary efficacy endpoint of statistical
non-inferiority in the clinical cure rate at the Test-Of-Cure
visit was achieved," Arpida said.
Read more at Reuters.com Government Filings News
and safety of iclaprim in the treatment of skin infections with
that of market leader linezolid, marketed by Pfizer as Zyvox.
"The pre-specified primary efficacy endpoint of statistical
non-inferiority in the clinical cure rate at the Test-Of-Cure
visit was achieved," Arpida said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment